Pancreatic Cancer Research

ResearcherDublin City UniversityActive in the last 2 years

Paula Meleady

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5306-310X; OpenAlex author ID A5018053019. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 7

  1. Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer. Co-author DOI 10.1016/j.biopha.2026.119273↗
  2. Multi-omic biomarker panel in pancreatic cyst fluid and serum predicts patients at a high risk of pancreatic cancer development. Co-author DOI 10.1038/s41598-024-83742-4↗
  3. Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Der… Co-author DOI 10.3390/life13030608↗
  4. Proteomic analysis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/14789450.2020.1803743↗
  5. Proteomic Analysis of Cell Lines and Primary Tumors in Pancreatic Cancer Identifies Proteins Expressed Only In Vitro and Only In Vivo. Co-author DOI 10.1097/mpa.0000000000001633↗
  6. A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts. Co-author DOI 10.3390/proteomes6040045↗
  7. Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact. Last author DOI 10.1586/14789450.2016.1167601↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kevin C. Conlon · 4 shared papers, 2018–2025 · strength 0.53
  2. Martin M. Clynes · 5 shared papers, 2016–2023 · strength 0.53
  3. Sandra Roche · 3 shared papers, 2018–2023 · strength 0.31
  4. Fiona O’Neill · 3 shared papers, 2018–2023 · strength 0.31
  5. Naomi Walsh · 1 shared paper, 2026 · strength 0.30
  6. Sara Noorani · 1 shared paper, 2026 · strength 0.30
  7. Jojanneke Stoof · 1 shared paper, 2026 · strength 0.30
  8. Orla Coleman · 3 shared papers, 2016–2020 · strength 0.24
  9. Paul F. Ridgway · 1 shared paper, 2025 · strength 0.22
  10. Laura E. Kane · 1 shared paper, 2025 · strength 0.22
  11. Stephen G. Maher · 1 shared paper, 2025 · strength 0.22
  12. Robert M. Straubinger · 2 shared papers, 2018–2023 · strength 0.21
  13. Rozana Abdul Rahman · 1 shared paper, 2020 · strength 0.15
  14. Taylor J. Allen-Coyle · 1 shared paper, 2023 · strength 0.14
  15. Ray McDermott · 1 shared paper, 2023 · strength 0.14
  16. Finbarr O’Sullivan · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.